Partial splenectomy has attracted increasing attention as an alternative to total splenectomy for the treatment of children with hereditary spherocytosis (HS) and other congenital hemolytic anemias. Total splenectomy, although quite effective for the treatment of HS, has been associated with a variety of significant complications, notably overwhelming post-splenectomy sepsis (OPSI). 
overwhelming post-splenectomy sepsis (OPSI). 1, 2 Other less recognized but potentially severe complications of splenectomy include increased risk for vascular thrombosis, vascular derangements such as hypertension and vascular disease, and various immunological impairments. [3] [4] [5] [6] [7] Given these concerns, the use of partial splenectomy as an alternative surgical option for the treatment of HS is attractive, with the goal of providing acceptable long-term hematological outcomes as well as preserving splenic function. In this article, we discuss what is known about the efficacy and safety of partial splenectomy in the treatment of HS. We also critically examine both what is known and what is not known about the success of partial splenectomy in the preservation of splenic function in these children.
Hereditary Spherocytosis
HS is the most common inherited red blood cell (RBC) membrane disorder in Northern Europe and North America, with an incidence of one in 5,000 births. HS results from a deficiency or dysfunction of one of the constituents of the RBC cytoskeleton (most commonly ankyrin and spectrin), which leads to shortened RBC lifespan. [8] [9] [10] [11] Most children with HS have a benign clinical phenotype and will not require surgical intervention; however, a subset of patients develop severe clinical sequelae of their disease, including accelerated hemolysis, hemolytic crises, splenic sequestration, sepsis, and gallstones. These severely affected children with HS have traditionally been treated with total splenectomy, resulting in improvement of anemia, reduced rates of hemolysis, elimination of splenic sequestration, and alleviation of symptoms associated with splenomegaly. 9 Despite the common misconception that total splenectomy is rarely employed in children with HS, the incidence and public health impact of children with HS requiring total splenectomy is substantial. The 2003
Healthcare Cost and Utilization Project (HCUP) Kids' Inpatient Database (KID), a robust and widely used measure of pediatric disorders, has estimated that the number of children 0-17 years of age with HS requiring total splenectomy is 373 children/year (HCUP Kids' Inpatient Database, ICD-9-CM category).
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Total Splenectomy and Splenic Function
The role of the spleen has been poorly understood for much of the history of medicine and surgery. Declared an organ unnecessary for life by Aristotle (382-322 BCE), the spleen was still considered completely expendable by Renaissance thinkers such as Andreus Vesalius (1514-1564 CE). This deeply held belief that the spleen is relatively unimportant paved the way for the first successful total splenectomy for trauma in 1678 CE by Nicholaus Matthias. 13 Although much has been learned about the physiology of the spleen over the last few centuries, we still do not completely understand its role nor fully understand the consequences of its removal. infections by encapsulated bacteria in children. 30 As infections with S. pneumoniae alone kill over one million children worldwide each year due to otitis media, pneumonia, and meningitis, increased susceptibility to this pathogen carries widespread public health consequences. The clinical consequences of this altered NO balance include potential increased long-term risks of hypertension, vascular thrombosis, pulmonary hypertension, and cardiovascular disease. 24 Finally, total splenectomy appears to lead to an increased risk for vascular thrombosis. Although the precise mechanisms are not understood, thromboembolic events ranging from portal vein thrombosis to deep vein thrombosis and pulmonary embolism occur in up to 10% of patients who undergo total splenectomy. [20] [21] [22] With improved diagnostic modalities, the incidence of thrombosis may prove to be even higher than is now clinically appreciated. Ikeda reported that the incidence of portal or splenic vein thrombosis after laparoscopic splenectomy is 55% as determined by abdominal computed tomography (CT).
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Partial Splenectomy and Splenic Function
Given the morbidity associated with use of total splenectomy, recently interest has grown in alternative surgical approaches for children with various clinical diseases. For children with congenital hemolytic anemias such as HS, a partial splenectomy is designed to resect enough spleen to achieve the desired hematological effect while leaving enough remnant tissue to preserve splenic function. Based on animal models that suggest that 20% of splenic mass will preserve the splenic phagocytic response to a challenge of S. pneumoniae, several groupsincluding ours-have adopted the goal of removing 80-90% of splenic tissue for most conditions, including HS. [25] [26] [27] The demonstration of preserved splenic function following partial splenectomy can be exceedingly complicated, as many different methods are used for assessing splenic function by various investigators. Methods for assessment of splenic function include clinical, laboratory, or radiographic measures (see Table 1 ). This group has reported a sustained decrease in hemolysis and an improvement in control of anemia in most children. In their most recent summary of 40 children one to 14 years of age, the mean hemoglobin level increased from 9.2±2.6g/dl at baseline to 12.3±1.9g/dl three to four years after surgery (p<0.01), with similar hemoglobin levels maintained for up to 10 years after surgery. Also, this group demonstrated preserved phagocytic function of the splenic remnant using radionuclide liver-spleen scan in most children.
Similarly, a group in the Czech Republic has published their experience with 14 children with HS undergoing partial splenectomy. 36 In this nonrandomized study, mean hemoglobin levels increased from 9.9 to Several groups in North America have begun to examine the role of partial splenectomy in children with HS (see Figure 1) . 32, 33, 37, 40 Our group, in collaboration with the Children's Hospital of Wisconsin, has a combined experience of partial splenectomy in over 60 children with HS. 33, 37 In our initial experience, we observed that mean hemoglobin levels increase by 2-3gm/dl compared with baseline at three months following surgery, a difference that persisted over 10 years of follow-up (p<0.05) (see Figure 2) . 33, 37 We also observed sustained control of hemolysis, as reticulocyte counts decreased from 12.7±4.2% preoperatively to 4.9±2.9% (mean ± standard deviation [SD]; p<0.05). Mean serum bilirubin levels decreased from a level of 2.6±1.1mg/dl preoperatively to 1.3±0.7mg/dl (mean ± SD; p<0.05). We have also noted that following partial splenectomy, splenic phagocytic function is preserved by the clearance of HJB. Interestingly, during the first month post-operatively, many children have detectable circulating HJB in the peripheral smear. However, this finding is transient, and only one child in our experience had detectable HJB during any future exam. Five children were tested post-operatively for pitted RBCs using Nomarski optics; three had normal levels (<2%) and two children had mildly elevated levels (3-6%). Preservation of many aspects of normal immune function was also observed among our patients who underwent partial splenectomy, consistent with the French experience.
U S H E M A T O L O G Y
At our center, seven children were tested at three years for Ig production, with maintenance of normal levels of IgG and IgM (IgG 
Concerns Regarding Partial Splenectomy
One concern often raised regarding partial splenectomy is that of re-growth of the splenic remnant. In the clinical studies to date, there has been variable splenic re-growth after partial splenectomy in some children as measured by sonographic measurement of splenic volume. In our experience, re-growth is initially slow, as the size of the splenic remnant remained between 15 and 30% of baseline volume throughout the first two years of follow-up, significantly below the pre-operative size (p<0.05). By four-year follow-up, the splenic re-growth was more pronounced, averaging 40% of original splenic size, although the rate of splenic re-growth is quite variable among children. Interestingly, in our experience, re-growth of the spleen did not appear to be associated with recurrent hemolysis, an observation also noted in the French experience.
One additional concern regarding partial splenectomy has been the feasibility of this approach in the setting of massive splenomegaly.
Although there are few published studies of partial splenectomy in this setting, we compared children with various congenital hemolytic anemias both with and without massive splenomegaly (defined as measured splenic volume >500ml) who underwent the procedure. We found that children both with and without massive splenomegaly had successful outcomes from partial splenectomy. Both groups demonstrated decreased transfusion requirements, increased hematocrit, decreased bilirubin levels, decreased reticulocyte counts, and elimination of splenic sequestration. 
